drugset
drugset / Trial / NCT04213105

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults

NCT04213105 ↗

Phase 1 Unknown 144 enrolled Qilu Pharmaceutical Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

A randomized, double-blind and parallel group study to compare the pharmacokinetic, safety and pharmacodynamic of QL1206 and Prolia® in healthy adults

Timeline

Start
2019-10-31
Primary completion
2020-10-31
Completion
2020-10-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Denosumab Monoclonal antibody 60 mg Subcutaneous

Indications

No indication recorded.